IndustryCompany release

ClearPoint Neuro Q3 revenue rises 36% to $12.1M on IRRAflow; 2026 guidance $48-50M

🇺🇸 ClearPoint Neuro, Inc. (CLPT) · Wed 28 Oct 2026

The brain and spine delivery device maker reported higher neurosurgery sales, a thinner gross margin and a first formal BLA submission by a partner in Huntington's disease.

ClearPoint Neuro, a US company whose devices support delivery of drugs and gene therapies to the brain and spine, reported third-quarter 2026 results on 28 October for the quarter ended 30 September. Revenue climbed 36% to $12.1m.

The neurosurgery navigation and therapy business grew 59%, which the company attributed largely to IRRAflow, a product it gained through the acquisition of IRRAS. The biologics and drug delivery business, which serves pharmaceutical and biotech partners, grew 11%.

ClearPoint noted that one of its partners has submitted a first formal biologics licence application (BLA) for a Huntington's disease therapy. The summary available does not identify the partner or the product, nor does it give a review timetable.

Gross margin fell to 58% in the quarter. The company now expects 2026 revenue of $48m to $50m. No further detail on the margin decline or the guidance assumptions was available at the time of writing.

What it means for your team

  • Sponsors of CNS gene and drug therapies should note that a BLA for Huntington's disease has now been submitted with a partner using ClearPoint's delivery technology, which may shape expectations for device-drug combination reviews.
  • Regulatory teams working on intracerebral delivery should expect delivery devices to be assessed alongside the biologic, though the company has not disclosed how this will apply in the submitted file.
  • Market-access teams can read the 11% growth in biologics and drug delivery as steady, rather than rapid, partner activity compared with the 59% growth in the neurosurgery segment.

Company's press release (SEC filing): ClearPoint Neuro, Inc. ↗

Article written by VigiEye from the official source (ClearPoint Neuro, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →